Losartan

• CAT Number: I000549
• CAS Number: 114798-26-4
• Molecular Formula: C22H23ClN6O
• Molecular Weight: 422.91
• Purity: ≥95%
• Target: Angiotensin Receptor
• Solubility: 10 mM in DMSO
• Storage: 2-8°C
• IC50: 20 nM
• IUPAC Name: [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
• InChI: InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
• InChIKey: PSIFNNKUMBGKDQ-UHFFFAOYSA-N
• SMILES: CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl

Losartan（Cat No.:I000549） is an angiotensin II receptor antagonist that effectively competes with angiotensin II for binding to AT1 receptors, displaying an IC50 value of 20 nM. By binding to AT1 receptors, losartan blocks the effects of angiotensin II, a hormone responsible for vasoconstriction and the release of aldosterone. This results in the relaxation of blood vessels, reduced blood pressure, and decreased aldosterone secretion. Losartan is commonly prescribed for the management of hypertension and may also be used to treat certain kidney conditions.

Reference

[1]. Burnier, M., Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.
[2]. Ashry, O., et al., Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.
[3]. Choi, C.H., et al., Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31.
[4]. Habashi, J.P., et al., Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21.
[5]. Campbell, D.J., A. Kladis, and A.J. Valentijn, Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40.